Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

To Heart “Fail” or Not? The Expanding Role of SGLT2 Inhibitors

To Heart “Fail” or Not? The Expanding Role of SGLT2 Inhibitors To Heart “Fail” or Not? The Expanding Role of SGLT2 Inhibitors MARTIN GORDON, PHARMD CANDIDATE JENNIFER N. CLEMENTS, PHARMD, FCCP, FADCES BCPS, CDCES, BCAC 28 28 / // / ADCES ADCES IN IN PRACTICE / PRACTICE // / Mar Marc ch 2 h 20 021 21 Persons with diabetes (PWD) are at a high risk of person with diabetes, there may be more glucose microvascular and macrovascular complications. reabsorption, especially when the amount of Typically, when discussing macrovascular glucose exceeds 180 g. complications, myocardial infarction (MI) and SGLT2 is located in the proximal convoluted stroke are often examples. PWD are informed tubule and responsible for 90% of glucose about the risk of developing these complications reabsorption. Through inhibition, glucose but also preventive measures for macrovascular excretion is promoted through the urine. This events. Acute MI and stroke can occur 10- to 20- specific and sole mechanism of action for fold more often in persons with type 2 diabetes the SGLT2 inhibitors can improve metabolic 1,2 (T2DM). Persons with this classification of parameters, such as reduction in glucose levels. This class of medication diabetes are also at a 2 to 4 times higher risk for In addition, glucose consists of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png ADCES in Practice SAGE

To Heart “Fail” or Not? The Expanding Role of SGLT2 Inhibitors

ADCES in Practice , Volume 9 (2): 6 – Mar 1, 2021

Loading next page...
 
/lp/sage/to-heart-fail-or-not-the-expanding-role-of-sglt2-inhibitors-aOHsQ693xR
Publisher
SAGE
Copyright
© 2021 by the American Association of Diabetes Educators
ISSN
2633-559X
eISSN
2633-5603
DOI
10.1177/2633559X20978321
Publisher site
See Article on Publisher Site

Abstract

To Heart “Fail” or Not? The Expanding Role of SGLT2 Inhibitors MARTIN GORDON, PHARMD CANDIDATE JENNIFER N. CLEMENTS, PHARMD, FCCP, FADCES BCPS, CDCES, BCAC 28 28 / // / ADCES ADCES IN IN PRACTICE / PRACTICE // / Mar Marc ch 2 h 20 021 21 Persons with diabetes (PWD) are at a high risk of person with diabetes, there may be more glucose microvascular and macrovascular complications. reabsorption, especially when the amount of Typically, when discussing macrovascular glucose exceeds 180 g. complications, myocardial infarction (MI) and SGLT2 is located in the proximal convoluted stroke are often examples. PWD are informed tubule and responsible for 90% of glucose about the risk of developing these complications reabsorption. Through inhibition, glucose but also preventive measures for macrovascular excretion is promoted through the urine. This events. Acute MI and stroke can occur 10- to 20- specific and sole mechanism of action for fold more often in persons with type 2 diabetes the SGLT2 inhibitors can improve metabolic 1,2 (T2DM). Persons with this classification of parameters, such as reduction in glucose levels. This class of medication diabetes are also at a 2 to 4 times higher risk for In addition, glucose consists of

Journal

ADCES in PracticeSAGE

Published: Mar 1, 2021

There are no references for this article.